Literature DB >> 12355181

The relative relevance of phosphorylation of the Thr(17) residue of phospholamban is different at different levels of beta-adrenergic stimulation.

Matilde Said1, Cecilia Mundiña-Weilenmann, Leticia Vittone, Alicia Mattiazzi.   

Abstract

Contractility and relaxation measurements were combined with the determination of total phospholamban (PLB) phosphorylation and the immunodetection of PLB-phosphorylation sites in the intact, beating rat heart to identify the contributions of PLB phosphorylation at the Thr(17) and Ser(16) residues at different levels of beta-adrenoceptor stimulation. Whereas with 30-300 nM isoproterenol, phosphorylation of Thr(17), the Ca(2+)-calmodulin-dependent protein kinase-II (CaMKII) site and Ser(16), the protein kinase A (PKA) site, contributed approximately 50% each to PLB phosphorylation, and both participated in the relaxant action of isoproterenol, at lower a level of beta-adrenoceptor stimulation (isoproterenol 0.3-3 nM), both effects were exclusively due to Ser(16) phosphorylation. Increasing [Ca](o) at 3 nM isoproterenol, to obtain an increase in contractility comparable to that produced by 30 nM isoproterenol, significantly increased Thr(17) phosphorylation and the relaxant effect produced by 3 nM isoproterenol. An increase in Thr(17) phosphorylation and in the relaxant effect of 3 nM isoproterenol was also obtained by phosphatase inhibition (okadaic acid). In this case, Ser(16) phosphorylation was also increased. Moreover, perfusion with 30 nM isoproterenol in the presence of the PKA inhibitor H-89 decreased phosphorylation at both PLB residues and diminished the inotropic and relaxant responses to the beta-agonist. The relative contribution of Thr(17) phosphorylation to the isoproterenol-induced phosphorylation of PLB and relaxation thus increased with the level of beta-adrenoceptor stimulation and the consequent increase in PKA activity. The lack of Thr(17) phosphorylation at low isoproterenol concentrations might therefore be attributed to a level of PKA activity insufficient to increase [Ca](i) to activate the CaMKII system and/or to inhibit the phosphatase that dephosphorylates PLB

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12355181     DOI: 10.1007/s00424-002-0885-y

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  8 in total

1.  Frequency-dependent acceleration of relaxation in mammalian heart: a property not relying on phospholamban and SERCA2a phosphorylation.

Authors:  Carlos A Valverde; Cecilia Mundiña-Weilenmann; Matilde Said; Paola Ferrero; Leticia Vittone; Margarita Salas; Julieta Palomeque; Martín Vila Petroff; Alicia Mattiazzi
Journal:  J Physiol       Date:  2004-11-04       Impact factor: 5.182

2.  Heart failure in mice induces a dysfunction of the sinus node associated with reduced CaMKII signaling.

Authors:  Jian-Bin Xue; Almudena Val-Blasco; Moran Davoodi; Susana Gómez; Yael Yaniv; Jean-Pierre Benitah; Ana María Gómez
Journal:  J Gen Physiol       Date:  2022-04-22       Impact factor: 4.000

Review 3.  Beta-adrenergic receptor signaling in the heart: role of CaMKII.

Authors:  Michael Grimm; Joan Heller Brown
Journal:  J Mol Cell Cardiol       Date:  2009-10-31       Impact factor: 5.000

4.  Phospholamban phosphorylation in ischemia-reperfused heart. Effect of pacing during ischemia and response to a beta-adrenergic challenge.

Authors:  Cecilia Mundiña-Weilenmann; Matilde Said; Leticia Vittone; Paola Ferrero; Alicia Mattiazzi
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

5.  Ca2+/calmodulin kinase II increases ryanodine binding and Ca2+-induced sarcoplasmic reticulum Ca2+ release kinetics during beta-adrenergic stimulation.

Authors:  Paola Ferrero; Matilde Said; Gina Sánchez; Leticia Vittone; Carlos Valverde; Paulina Donoso; Alicia Mattiazzi; Cecilia Mundiña-Weilenmann
Journal:  J Mol Cell Cardiol       Date:  2007-06-06       Impact factor: 5.000

6.  Phosphoproteomic analysis identifies phospho-Threonine-17 site of phospholamban important in low molecular weight isoform of fibroblast growth factor 2-induced protection against post-ischemic cardiac dysfunction.

Authors:  Janet R Manning; Aruna B Wijeratne; Brian B Oloizia; Yu Zhang; Kenneth D Greis; Jo El J Schultz
Journal:  J Mol Cell Cardiol       Date:  2020-08-25       Impact factor: 5.000

Review 7.  The role of CaMKII regulation of phospholamban activity in heart disease.

Authors:  Alicia Mattiazzi; Evangelia G Kranias
Journal:  Front Pharmacol       Date:  2014-01-27       Impact factor: 5.810

8.  TSH inhibits SERCA2a and the PKA/PLN pathway in rat cardiomyocytes.

Authors:  Jiajia Dong; Cuixia Gao; Jing Liu; Yunshan Cao; Limin Tian
Journal:  Oncotarget       Date:  2016-06-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.